Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Post procedural haemorrhage? 15 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Post procedural haemorrhage have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 0.0% of all adverse event reports for PEMBROLIZUMAB.

15
Reports of Post procedural haemorrhage with PEMBROLIZUMAB
0.0%
of all PEMBROLIZUMAB reports
2
Deaths
12
Hospitalizations

How Dangerous Is Post procedural haemorrhage From PEMBROLIZUMAB?

Of the 15 reports, 2 (13.3%) resulted in death, 12 (80.0%) required hospitalization, and 1 (6.7%) were considered life-threatening.

Is Post procedural haemorrhage Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 15 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Post procedural haemorrhage?

LEVONORGESTREL (1,106) RIVAROXABAN (930) ASPIRIN (618) APIXABAN (539) ADALIMUMAB (476) IBRUTINIB (269) CLOPIDOGREL BISULFATE (235) HEPARIN (174) WARFARIN (170) DABIGATRAN ETEXILATE (121)

Which PEMBROLIZUMAB Alternatives Have Lower Post procedural haemorrhage Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Post procedural haemorrhage Reports All Drugs Causing Post procedural haemorrhage PEMBROLIZUMAB Demographics